Researchers discover dementia-like behaviour in pre-cancer cells

Cancer Research UK-funded scientists have uncovered dementia-like behaviour in pancreas cells at risk of turning into cancer. The findings provide clues that could help in the treatment and prevention of pancreatic cancer, a difficult-to-treat disease linked to 6,900 deaths in the UK every year.*

The research was published today (15 August) in the journal Developmental Cell**, and was funded by Cancer Research UK, with additional support from Wellcome, the Medical Research Council, and the Biotechnology and Biological Sciences Research Council.

Researchers from the Cancer Research UK Scotland Centre studied pancreas cells in mice over time, to see what was causing healthy cells to turn into cancer cells. They discovered that pancreatic cells at risk of becoming cancerous, known as pre-cancers, develop faults in the cell’s recycling process (known as “autophagy”).

In pre-cancer cells, the researchers noticed excess “problem protein” molecules forming clumps – behaviour seen in neurological diseases such as dementia. The researchers also noticed similar clumping occurring in human pancreas samples, suggesting this happens during pancreatic cancer development.

Cancer Research UK Senior Fellow at the Institute of Genetics and Cancer at the University of Edinburgh, Professor Simon Wilkinson, said:

“Our research shows the potential role autophagy disruption plays in the beginnings of pancreatic cancer. While early stage, we can potentially learn from research into other diseases where we see protein clumping, such as dementia, to better understand this aggressive type of cancer and how to prevent it.”

Although survival for many types of cancer has improved over recent decades, this has not been the case for pancreatic cancer. This is partly because it is often diagnosed at a late stage, where treatment options are limited.*** To address this, the researchers wanted to learn more about what may be causing pancreas cells to turn into cancer.

Multiple cancer types, including pancreatic cancer, are linked to a faulty mutation in a gene called KRAS, but scientists are increasingly learning that genetic changes are not the whole story.

One of the ways cells keep people healthy is by breaking down excess molecules they no longer need, through a recycling process called “autophagy”. Autophagy is particularly important in the pancreas to control the level of digestive proteins and hormones the pancreas produces to help break down food.

Scientists have studied autophagy in detail over many years and are learning the key role it plays in diseases such as cancer. In some cases, cancer cells can become “addicted” to autophagy, hijacking the recycling process to help cancer cells divide and grow more quickly****.

This research, on the other hand, suggests the combined effect of the faulty KRAS gene and disrupted autophagy could be driving the development of pancreatic cancer. The researchers plan to study these processes in more detail, to see if they can help predict or possibly reverse the start of pancreatic cancer, and if factors like age, sex, or diet play a role.

Executive Director of Research and Innovation at Cancer Research UK, Dr Iain Foulkes, said: 

“Around 10,500 people are diagnosed with pancreatic cancer in the UK each year and, sadly, too many of those cases are found at a stage where treatment options are limited. While further work is needed, these findings could provide vital clues into how we can better understand how pancreatic cancer develops.” 

Research into pancreatic cancer is one of Cancer Research UK’s top priorities. We fund research into the causes of pancreatic cancer, tests to diagnose the disease, and clinical trials designed to look at improving treatment, reducing side effects, and controlling symptoms***.

The paper, titled “ER-phagy and proteostasis defects prime pancreatic epithelial state changes in KRAS-mediated oncogenesis” was published today (15 August) in Developmental Cell**.

ENDS 

Professor Simon Wilkinson and other Cancer Research UK spokespeople are available for interview. For media enquiries, contact Fiona Scott in the Cancer Research UK press office via fiona.scott@cancer.org.uk or on 020 3469 5128 and, out of hours, on 020 3469 8301. 

Notes to Editor 

*Pancreatic cancer statistics. Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer. Accessed July 2025.

**The paper will be available from here when the embargo lifts. An accepted version of the paper is available on request.

***Research into pancreatic cancer. Cancer Research UK. https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/research-clinical-trials/pancreatic-cancer. Accessed July 2025.

****Pimentel et al. Autophagy and cancer therapy. Cancer Letter. 2024. doi: 10.1016/j.canlet.2024.217285.

About Cancer Research UK:

1. Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence, and information.

1. Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.

1. Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 50 years.

1. Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK wants to accelerate progress and see 3 in 4 people surviving their cancer by 2034.

1. Cancer Research UK supports research into the prevention and treatment of cancer through the work of over 4,000 scientists, doctors, and nurses.

1. Together with its partners and supporters, Cancer Research UK is working towards a world where people can live longer, better lives, free from the fear of cancer.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook